Education
About Us
Working with TipRanks
Follow Us
Aziyo Biologics (ELUT)
NASDAQ:ELUT
Top Page
Aziyo Biologics
(NASDAQ:ELUT)
43Neutral
Positive Factors
Financial Stability
Elutia's financial position remains solid with $26M of cash, supporting continued operations and strategic initiatives.
Product Uptake
Product uptake for EluPro is robust, with substantial same-center sales growth and over 100 active accounts, indicating strong market acceptance.
Strategic Partnership
Distribution partner Boston Scientific’s 900 person EP focused sales organization will be able to offer EluPro in its implant cases, expected to provide a significant tailwind.
Negative Factors
Business Segment Performance
Q4 revenue shortfall was related to the Women’s Health business (SimpliDerm) as partner Tiger continues through its reorganization process.
Product Performance
SimpliDerm was below expectations in Q4 due to partner Tiger working through its reorganization process.
Revenue Challenges
Revenue was below expectations due to non-core cardiovascular performance and bio-envelope cannibalization.
Aziyo Biologics (ELUT) vs. S&P 500 (SPY)
Market Cap
$76.83M
Dividend YieldN/A
Average Volume (3M)40.16K
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue Growth-31.04%
EPS Growth11.34%
CountryUS
Employees51
SectorHealthcare
Sector Strength54
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.21
Shares Outstanding36,552,350
10 Day Avg. Volume42,033
30 Day Avg. Volume40,156
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.17
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.00Price Target Upside368.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aziyo Biologics Business Overview & Revenue Model
Company DescriptionAziyo Biologics, Inc. (ELUT) is a regenerative medicine company dedicated to developing and delivering innovative products to improve patient outcomes. The company operates primarily in the medical device and biotechnology sectors, focusing on the commercialization of biologic solutions for use in various therapeutic areas, including cardiology, orthopedics, and wound care. Aziyo's core products are designed to enhance tissue repair and regeneration, leveraging proprietary technologies to address significant unmet medical needs.
How the Company Makes MoneyAziyo Biologics generates revenue through the sale of its biologic products and solutions to healthcare providers, hospitals, and medical institutions. The company's key revenue streams include direct sales of its medical devices and biologics, as well as partnerships with other healthcare companies that distribute and utilize Aziyo's products. Aziyo's earnings are significantly influenced by its ability to innovate and expand its product portfolio, strategic collaborations with industry leaders, and its effectiveness in navigating regulatory pathways to bring new products to market.
Aziyo Biologics Financial Statement Overview
Summary
Aziyo Biologics is facing significant financial difficulties, with declining revenue, profitability issues, high leverage, and negative cash flows. The company needs to address its debt levels and improve operational efficiency to stabilize its financial position and enhance shareholder value.Income Statement
Aziyo Biologics has been experiencing declining revenue and increasing losses over the years. The gross profit margin is shrinking, and net income has been consistently negative, indicating profitability challenges. Revenue decreased in 2024 compared to 2023, highlighting a concerning trend. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies.45
Neutral
Balance Sheet
The balance sheet reveals a high level of debt and a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not applicable due to negative equity, but the company is clearly highly leveraged. Total assets have decreased, and the equity ratio is negative, signifying financial distress.30
Negative
Cash Flow
Operating cash flow and free cash flow are negative, which raises concerns about the company's ability to generate cash from operations. Free cash flow has been declining, and there is a significant reliance on financing activities to cover cash shortfalls. The operating cash flow to net income ratio is not favorable, reflecting cash flow challenges.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 24.38M | 24.75M | 23.85M | 47.39M | 42.68M | Gross Profit |
| 10.71M | 11.05M | 11.64M | 19.02M | 20.56M | EBIT |
| -35.65M | -30.53M | -29.99M | -23.03M | -13.60M | EBITDA |
| -45.89M | -31.92M | -27.46M | -15.72M | -12.30M | Net Income Common Stockholders |
| -53.95M | -37.66M | -32.90M | -24.83M | -21.82M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 13.24M | 19.28M | 16.99M | 30.43M | 39.53M | Total Assets |
| 36.13M | 43.43M | 68.84M | 67.17M | 82.81M | Total Debt |
| 30.23M | 23.95M | 39.40M | 44.99M | 52.31M | Net Debt |
| 16.99M | 4.68M | 22.41M | 14.56M | 12.78M | Total Liabilities |
| 82.39M | 82.03M | 73.87M | 53.65M | 61.98M | Stockholders Equity |
| -46.26M | -38.60M | -5.03M | 13.52M | 20.83M |
| Cash Flow | Free Cash Flow | |||
| -22.66M | -22.11M | -22.44M | -15.99M | -14.07M | Operating Cash Flow |
| -22.66M | -21.76M | -21.90M | -15.62M | -13.44M | Investing Cash Flow |
| -474.00K | 14.21M | -540.00K | -369.00K | -640.00K | Financing Cash Flow |
| 17.09M | 9.84M | 9.00M | 6.88M | 51.02M |
Aziyo Biologics Technical Analysis
Negative
1.92
Price Trends
2.58
Negative
2.96
Negative
3.37
Negative
Market Momentum
-0.17
Positive
39.28
Neutral
21.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELUT, the sentiment is Negative. The current price of 1.92 is below the 20-day moving average (MA) of 2.15, below the 50-day MA of 2.58, and below the 200-day MA of 3.37, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 39.28 is Neutral, neither overbought nor oversold. The STOCH value of 21.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELUT.
Aziyo Biologics Risk Analysis
Aziyo Biologics disclosed 77 risk factors in its most recent earnings report. Aziyo Biologics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aziyo Biologics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.21B | 3.55 | -41.91% | 2.83% | 15.12% | 0.42% | |
46 Neutral | $89.76M | ― | -42.83% | ― | ― | 48.92% | |
43 Neutral | $76.83M | ― | 149.62% | ― | -31.04% | 11.34% | |
41 Neutral | $100.12M | ― | -45.55% | ― | 98.56% | 37.97% | |
36 Underperform | $87.30M | ― | -80.74% | ― | ― | ― | |
33 Underperform | $70.52M | ― | -94.52% | ― | ― | 2.98% |
* Healthcare Sector Average
Performance Comparison
ELUT
Aziyo Biologics
1.99
-1.30
-39.51%
ZNTL
Zentalis Pharmaceuticals
1.26
-11.28
-89.95%
CCCC
C4 Therapeutics
1.54
-4.62
-75.00%
VOR
Vor Biopharma
0.16
-1.55
-90.64%
KYTX
Kyverna Therapeutics, Inc.
2.13
-11.87
-84.79%
Aziyo Biologics Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: -3.52%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call reflected a positive outlook with significant achievements such as the successful launch of EluPro, strategic partnerships, and manufacturing expansions. Financial strength was demonstrated despite a decline in Simploderm revenue and litigation-related expenses.Q1-2025 Updates
Positive Updates
Successful Launch of EluPro
EluPro's first full quarter launch exceeded expectations, with an 84% increase from the fourth quarter. It now constitutes 52% of BioEnvelope revenue, driven by approvals from 25 hospitals actively ordering the product.
Partnership with Boston Scientific
The partnership includes 900 sales professionals promoting EluPro, resulting in sales at over 52 hospitals. This collaboration aims to expand market reach and accelerate product adoption.
Manufacturing Expansion
A new facility in Gaithersburg, Maryland, was opened to expand manufacturing capacity for the antibiotic disc, reducing costs and removing supply constraints.
Financial Position Strengthening
The company reported a 31% year-over-year growth in BioEnvelope division revenue, improved sequential growth, and a successful cash position with $17.4 million at quarter's end.
Edison Award and Scientific Recognition
EluPro received an Edison Award for innovation in postsurgical recovery and a peer-reviewed publication confirming its broad-spectrum antibacterial effect.
Negative Updates
Simploderm Revenue Decline
Simploderm revenue decreased from $3.6 million last year to $2.6 million this quarter, although it showed a 13% increase from Q4.
Litigation Settlement Impact
Cash flow from operations included a $4 million settlement of litigation, affecting the financials but expected to be resolved by Q2.
Company Guidance
During the Elutia Inc. First Quarter 2025 Financial Results Conference Call, significant guidance was given regarding various metrics. EluPro's first quarter launch was emphasized as a major success with a substantial performance increase, constituting 52% of BioEnvelope revenue, jumping 84% from the fourth quarter, and contributing to a 31% year-over-year growth of $3.1 million for the BioEnvelope division. The company's strategic partnership with Boston Scientific, which boosts their sales force to over 900 reps, was highlighted as a key factor for future growth, with 52 hospitals already engaged. Capacity expansion efforts included a new facility in Gaithersburg, Maryland, to support the production of critical components, aiming to support annual revenues of up to $140 million at 70%+ gross margins. Financially, the company reported a total revenue of $6 million for the quarter, with a 54.8% adjusted gross margin, and a reduction in operating expenses, leading to an adjusted EBITDA of $3.3 million. Cash conservation strategies were also outlined, including amendments with financial partners to support liquidity.Aziyo Biologics Corporate Events
Business Operations and StrategyFinancial Disclosures
Elutia Inc. Reports Strong Q1 2025 Financial Results
Positive
May 8, 2025
Elutia Inc. announced amendments to its royalty agreement with Ligand Pharmaceuticals, converting $2.2 million in royalty obligations into shares of Elutia’s Class A Common Stock, which impacts cash flow positively by reducing outflows. Additionally, Elutia reported strong first-quarter 2025 financial results, driven by an 84% increase in EluPro sales and a strategic partnership with Boston Scientific, which is expected to accelerate product adoption and enhance market positioning.
Spark’s Take on ELUT Stock
According to Spark, TipRanks’ AI Analyst, ELUT is a Underperform.
Elutia Inc. faces substantial financial and operational challenges, with declining revenues and high leverage. Technical indicators are bearish, and valuation metrics are unattractive. While the earnings call provided some positive news with EluPro’s adoption and margin improvements, these are overshadowed by the broader financial difficulties, leading to a weak overall stock outlook.
To see Spark’s full report on ELUT stock, click here.
Product-Related AnnouncementsBusiness Operations and Strategy
Elutia Inc. Ends Distribution Agreement with LeMaitre
Positive
May 6, 2025
On April 30, 2025, Elutia Inc. ended its distribution agreement with LeMaitre Vascular, Inc., transitioning to direct distribution of its cardiovascular products in the U.S. This strategic move is expected to enhance Elutia’s top-line growth, improve gross margins, and increase profitability. Under the leadership of Dwayne Montgomery, Elutia has established a dedicated cardiovascular sales team to ensure a smooth transition and continuity for customers. The company anticipates maintaining a premium price position and achieving approximately 80% gross margins for its cardiovascular portfolio.
Spark’s Take on ELUT Stock
According to Spark, TipRanks’ AI Analyst, ELUT is a Neutral.
Elutia Inc. faces significant financial challenges, with declining revenue and high leverage contributing to a low financial performance score. Technical indicators suggest a bearish trend, and valuation metrics are unattractive due to negative earnings. However, the earnings call highlighted some positive developments with EluPro’s adoption and improved gross margins, slightly offsetting the negative factors. Overall, the stock’s outlook remains weak due to these substantial financial and operational challenges.
To see Spark’s full report on ELUT stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.